Key result
Fondaparinux and idraparinux prolonged coagulation times in the PiCT, Heptest, and chromogenic FXa assays in a dose-dependent manner in pooled human normal plasma.
Why the study?
Does the prothrombinase-induced clotting time (PiCT) assay accurately measure the anticoagulant effects of fondaparinux and idraparinux in human plasma?
Does the prothrombinase-induced clotting time (PiCT) assay accurately measure the anticoagulant effects of fondaparinux and idraparinux in human plasma?
PiCT is a suitable assay to determine the anticoagulant effects of the new FXa inhibitors fondaparinux and idraparinux.
No takes yet. Share an insight, caveat, or question.
PiCT may support FXa inhibitor monitoring in plasma; leaves open clinical validation before practice adoption.
Harenberg et al. (2007) studied this question. Fondaparinux and idraparinux vs. Dalteparin was evaluated on Coagulation times. Fondaparinux and idraparinux prolonged coagulation times in the PiCT, Heptest, and chromogenic FXa assays in a dose-dependent manner in pooled human normal plasma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: